Nurix Therapeutics, Inc. — Form 10-K Summary
Period: Fiscal year ended November 30, 2020; comparative year ended November 30, 2019. The request metadata says “2019 Q4,” but the supplied filing is the company’s FY2020 annual report, not a standalone 2019 fourth-quarter filing.
Business context and reporting period
Nurix is a clinical-stage biopharmaceutical company developing small-molecule therapies that alter cellular protein levels through its DELigase platform. Its wholly owned programs target BTK degradation and CBL-B inhibition, with an additional drug-enhanced cell therapy program. The company had no approved products and no product-sale revenue. The company completed its IPO in July 2020.
Financial performance and position
| Metric | FY2020 | FY2019 |
|---|---|---|
| Collaboration revenue | $17.8 million | $31.1 million |
| Research and development expense | $66.5 million | $45.0 million |
| General and administrative expense | $16.3 million | $8.3 million |
| Loss from operations | $65.0 million | $22.2 million |
| Net loss | $43.2 million | $21.7 million |
| Net loss per share, basic and diluted | $2.76 | $6.59 |
| Cash used in operating activities | $0.1 million | Cash provided: $0.6 million |
FY2020 operating loss was approximately 365% of collaboration revenue; this is a loss-making development business, so conventional profitability margins are not meaningful. The smaller net loss than pre-tax loss reflects a $20.5 million income-tax benefit, primarily from CARES Act NOL carryback claims and related tax-reserve changes.
At November 30, 2020, cash and cash equivalents were $119.4 million, short-term investments $161.8 million, and long-term investments $90.9 million, for approximately $372.0 million in cash, cash equivalents and investments. Working capital was $253.9 million. The balance sheet reports no borrowings; liabilities included $93.5 million of deferred revenue and $15.1 million of other current and long-term liabilities. Operating lease commitments totaled $15.1 million, with the main San Francisco lease extending to April 2025.
Investing cash outflow was $254.4 million, principally reflecting investment purchases, not solely operating expenditure. Financing provided $339.0 million, mainly from $218.1 million net IPO proceeds and $119.9 million net proceeds from the Series D preferred-stock financing. Management said existing cash, cash equivalents and investments were expected to fund operations for at least 12 months after the financial statements were issued.
Changes versus the prior year
- Revenue fell 42.7%, chiefly because the Celgene collaboration ended in June 2019 and generated no FY2020 revenue. This was partly offset by higher Gilead revenue and $5.7 million recognized under the new Sanofi collaboration.
- R&D expense rose 47.7%, reflecting greater discovery and preclinical activity, hiring, and preparation for clinical programs. G&A expense nearly doubled, largely due to increased personnel, stock compensation, audit, legal, insurance and public-company costs.
- Net loss approximately doubled, while cash and investments rose substantially following the Series D financing and IPO. Preferred shares converted to common stock in connection with the IPO.
Outlook, risks and unusual items
- Program outlook at filing: FDA cleared the NX-2127 IND in January 2021; first-patient dosing in Phase 1 was expected in Q1 2021. Phase 1 trials for NX-5948, NX-1607 and DeTIL-0255 were planned for the second half of 2021. These were forward-looking plans, not reported trial outcomes.
- Collaborations: As of November 30, 2020, Nurix reported potential future fees and milestones of up to approximately $2.5 billion under Sanofi and $2.3 billion under Gilead, plus potential royalties. These amounts are contingent and not assured. Sanofi’s January 2021 target expansion added a $22 million payment and increased its target count from three to five.
- Development and safety: Product candidates remained early-stage, with efficacy and safety unproven in humans. Exploratory high-dose NX-2127 nonhuman-primate studies reported bruising, muscle degeneration, facial swelling and internal hemorrhage; the filing noted observations were absent or mild at lower clinically relevant doses. Immune overactivation and cytokine storm are among the stated CBL-B program risks.
- Funding and execution: Nurix expected continuing losses and substantial additional funding needs. It relies on third-party manufacturers and CROs, generally without long-term supply commitments or redundant drug-substance sources. COVID-19 could disrupt trials, suppliers and operations.
- Intellectual property: The company reported patent applications but no issued patents covering its product candidates at the time described. It also disclosed a third-party patent that could be asserted to cover CTMs, potentially including NX-2127.
- Controls and unusual reporting item: Disclosure controls were deemed ineffective because of an unremediated material weakness in financial reporting controls. The weakness contributed to a revision of Q3 2020 weighted-average shares and loss per share; the filing said the prior-period error was not material. The auditor gave an unqualified opinion on the financial statements. Q2 2020 reported net income of $7.6 million, an unusual quarterly result driven by tax benefits rather than operating profitability.
- Contingencies: Management reported no pending or threatened litigation considered material and no material legal proceedings. The filing describes routine indemnification obligations whose maximum potential exposure was not determinable.
Important facts for investors to verify
- Whether planned Phase 1 trials began on schedule and what subsequent safety, pharmacology and efficacy data show.
- Cash and investment balances, operating cash burn, and the timing and conditions of any additional financing or collaboration payments.
- Progress in remediating the material weakness and whether financial reporting controls are subsequently found effective.
- Patent prosecution outcomes and any developments concerning the disclosed third-party CTM patent risk.
- Manufacturing and clinical-supply readiness, including exposure to single-source vendors and COVID-19-related disruption.
- Whether collaboration milestones are achieved; headline maximum payments should not be treated as committed or forecast revenue.